# Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

> **NCT06350097** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 582 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Datopotamab Deruxtecan

## Key facts

- **NCT ID:** NCT06350097
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-29
- **Primary completion:** 2028-03-21
- **Final completion:** 2031-08-29
- **Target enrollment:** 582 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06350097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06350097, "Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06350097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*